Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
11.86
+0.42 (3.67%)
May 12, 2025, 4:00 PM - Market closed
Exicure Revenue
In the year 2024, Exicure had annual revenue of $500.00K.
Revenue (ttm)
$500.00K
Revenue Growth
n/a
P/S Ratio
48.47
Revenue / Employee
$71,429
Employees
7
Market Cap
74.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 500.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 28.83M | 29.31M | -6,068.12% |
| Dec 31, 2021 | -483.00K | -17.10M | -102.91% |
| Dec 31, 2020 | 16.61M | 15.32M | 1,181.87% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
XCUR News
- 7 days ago - Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
- 4 weeks ago - Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma - Business Wire
- 4 weeks ago - Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - Business Wire
- 7 weeks ago - Exicure, Inc. Reports Full Year 2024 Financial Results - Business Wire
- 2 months ago - Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia - Business Wire
- 3 months ago - CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. - Business Wire
- 3 months ago - Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. - Business Wire
- 4 months ago - Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech - Business Wire